🟠 Moderate Evidence
Vitamin B12 deficiency creates a metabolic trap that inactivates folate despite adequate dietary intake, preventing DNA synthesis and triggering megaloblastic anemia in bone marrow. This mechanism, documented in research published in the British Journal of Haematology (2006), explains why patients with B12 deficiency develop anemia even when folate levels appear normal on standard testing.
Key takeaways
- During B12 deficiency, 94.5% of red blood cell folate becomes trapped in an unusable form (5-methylTHF), compared to 67.4% after B12 repletion
- The enzyme methionine synthase, which requires B12 as a cofactor, is the only exit route from this trapped folate form—without B12, it remains inactive
- Global DNA methylation drops by 22% during B12 deficiency, and homocysteine accumulates to three times normal levels (52.9 vs. 16.8 nmol/L after repletion)
- Megaloblastic anemia results from depletion of THF, the active folate form needed for DNA replication in rapidly dividing cells
Study at a Glance
| Source | British Journal of Haematology |
| Study type | Case study with biochemical analysis |
| Population | B12-deficient patient (homozygous MTHFR C677T polymorphism) |
| Key measurement | RBC folate distribution, DNA methylation, homocysteine levels |
| Year published | 2006 |
The B12-folate trap: folate distribution shifts after B12 repletion
Red blood cell folate as 5-methylTHF (trapped form), percentage of total folate
Source: Smulders et al., British Journal of Haematology, 2006 | Georgian Medical Journal News
How the folate trap forms at the molecular level
Folate exists in multiple chemical forms inside cells, cycling through a series of transformations essential for DNA synthesis and methylation reactions. The critical enzyme MTHFR (methylenetetrahydrofolate reductase) converts 5,10-methyleneTHF into 5-methylTHF in an irreversible reaction documented in the Proceedings of the National Academy of Sciences (2017). Once folate enters this methyl form, it becomes a metabolic dead-end without functional B12.
The only exit from 5-methylTHF requires the enzyme methionine synthase, which must strip the methyl group from trapped folate while simultaneously converting homocysteine to methionine. This enzyme absolutely requires methylcobalamin, the active form of vitamin B12, as a cofactor. When B12 is deficient, methionine synthase cannot function, leaving folate permanently trapped in the 5-methylTHF form.
Consequences for DNA synthesis and blood cell formation
The metabolic consequences of this trap are profound. As 5-methylTHF accumulates, the active form of folate needed for DNA synthesis—THF and its derivatives—becomes depleted. DNA replication requires THF-derived thymidylate, the nucleotide building block for DNA synthesis. Without adequate THF, rapidly dividing cells in bone marrow cannot complete DNA replication during cell division.
Red blood cell precursors in particular are affected because they divide rapidly to maintain circulating red cell counts. Unable to replicate their DNA properly, these cells enlarge without dividing—a condition called megaloblastic anemia. The Smulders et al. case study documented this directly, showing that global DNA methylation was 22% lower during B12 deficiency. Simultaneously, homocysteine accumulated to dangerous levels—52.9 nmol/L during deficiency compared to 16.8 after B12 repletion—because methionine synthesis was impaired.
During B12 deficiency, 94.5% of red blood cell folate was trapped as 5-methylTHF, with DNA methylation reduced by 22% and homocysteine elevated to 52.9 nmol/L. After B12 supplementation, trapped folate fell to 67.4%, DNA methylation normalized, and homocysteine dropped to 16.8 nmol/L.
— Smulders et al., British Journal of Haematology (2006)
Clinical implications: why folate levels alone don’t detect functional deficiency
This mechanism has profound diagnostic implications. Standard laboratory testing measures total serum folate and red cell folate, but these tests cannot distinguish between active (usable) and trapped folate. A patient with B12 deficiency may have apparently “normal” folate levels on routine testing, yet experience functional folate deficiency at the cellular level. This means symptoms of megaloblastic anemia—fatigue, dyspnea, neurological symptoms—can develop despite adequate folate intake and normal folate measurements.
The patient in the Smulders case study carried a homozygous MTHFR C677T polymorphism, which further reduces MTHFR enzyme activity and may amplify the trapping effect. The authors described their findings as “the first time that virtually all features of the methylfolate trap hypothesis have been demonstrated in a human,” validating decades of biochemical theory through direct measurement in a living patient.
See also our coverage of clinical updates on vitamin B12 assessment and supplementation and pharmacy guidance on B12 and folate interactions.
What this means
Frequently asked questions
Can you have normal folate levels but still be folate deficient?
Yes, if you have B12 deficiency. According to Smulders et al. (2006), B12 deficiency traps folate in an unusable form (5-methylTHF), making standard folate tests misleading. Total folate measured in the lab may appear normal because it includes trapped folate, but the active folate available for DNA synthesis is depleted. This is why clinicians should measure B12 and homocysteine alongside folate, not folate alone.
What is the methylfolate trap and why does B12 deficiency cause it?
The methylfolate trap occurs when B12 deficiency inactivates methionine synthase, the only enzyme that can remove the methyl group from 5-methylTHF and return folate to its active forms. B12 serves as the cofactor for methionine synthase; without it, the enzyme cannot function. Folate becomes stuck in 5-methylTHF, accumulating while the active THF form needed for DNA synthesis is depleted. Field et al. (2017) documented the metabolic basis of this mechanism in detail.
How is B12 deficiency treated and does it reverse the folate trap?
B12 deficiency is treated through dietary sources (meat, fish, dairy, fortified grains), oral supplements, or injections—the route depends on the underlying cause. B12 injections are used if gastrointestinal malabsorption is the cause. Once B12 is repleted, methionine synthase becomes active again, the methylfolate trap is released, and folate returns to its active forms. In the Smulders case, B12 repletion reduced trapped folate from 94.5% to 67.4%, normalized DNA methylation, and reduced homocysteine to normal within weeks.
The methylfolate trap explains why B12 deficiency causes anemia even when patients consume adequate dietary folate and why supplementing folate alone is ineffective if B12 deficiency is the root cause. Clinicians managing anemia, elevated homocysteine, or neurological symptoms should assess B12 status directly rather than relying on folate measurements alone. Future research into rapid diagnostic tests that measure active folate rather than total folate could enable earlier detection and prevention of this preventable form of functional folate deficiency.
Source: Smulders et al., British Journal of Haematology (2006) and Field et al., Proceedings of the National Academy of Sciences (2017)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
